

Radioligand Therapy Market to Reach USD \$9.75 Billion by 2029 at 10.1% CAGR

*The Business Research Company's
Radioligand Therapy Global Market
Report 2025 – Market Size, Trends, And
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, September 15, 2025

/EINPresswire.com/ -- What Is The
Estimated Industry Size Of [Radioligand
Therapy Market?](#)



In the past few years, the radioligand therapy market has seen swift expansion. The market is projected to surge from \$6.01 billion in 2024 to \$6.64 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.5%. Several factors have contributed to the historical growth phase, including the increased application of liquid biopsy, the introduction of tumor-agnostic treatments, the incorporation of artificial intelligence within oncology, the robust pipeline of bispecific antibodies, and enhanced government financial support for cancer research.



Get 30% Off All Global
Market Reports With Code
ONLINE30 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors”

*The Business Research
Company*

In the coming years, the market size for radioligand therapy is anticipated to experience swift expansion. By 2029, it is projected to swell to \$9.77 billion, showing a compound annual growth rate (CAGR) of 10.2%. This projected growth during the forecast period can be

ascribed to several factors. These include heightened investment from major pharmaceutical companies in oncology startups, increased utilization of real-world evidence, advancements in radiopharmaceutical and theranostic research, synergies between academic institutions and industry, and an uptick in cases of rare and orphan cancers. Notable trends for the forecast period encompass AI-guided radiopharmaceutical formulation, theranostics integrating dual imaging-therapy platforms, microfluidics-powered radiotracer synthesis, next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

Download a free sample of the radioligand therapy market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp>

What Are The Major Factors Driving The Radioligand Therapy Global Market Growth?

The growth of the radioligand therapy market is anticipated to be fueled by the rising prevalence of cancer. Cancer, a disease characterized by an unchecked proliferation and spread of abnormal cells, is seeing an increase in incidence due to chronic exposure to environmental pollutants which impair cell function, damage DNA, and foster abnormal cell growth. Radioligand therapy combats cancer by directing radiation towards tumor cells via ligands that attach to specific receptors, reducing damage to healthy tissues and internally destroying cancer cells. For example, the American Cancer Society, a US-based non-profit organization promoting cancer awareness, reported in January 2022 that it is estimated there will be 1.9 million new cancer cases and 609,360 cancer-related deaths in the US, equating to nearly 1,670 deaths daily. Consequently, the rising incidence of cancer is promoting the expansion of the radioligand therapy market.

Who Are The Leading Companies In The Radioligand Therapy Market?

Major players in the Radioligand Therapy Global Market Report 2025 include:

- Bayer AG
- Novartis AG
- Eli Lilly and Company
- Lantheus Holdings Inc.
- Curium LLC
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Molecular Partners AG
- Telix Pharmaceuticals
- Nanobiotix S.A.
- Mariana Oncology Inc.

What Are The Major Trends That Will Shape The Radioligand Therapy Market In The Future?

Key players in the radioligand therapy market are concentrating their efforts on creating innovative solutions, such as facilities specifically for radioligand therapy. These facilities strive to improve production efficiency and adhere to stringent standards of quality and safety when manufacturing and distributing targeted cancer treatments. These specialized centers are equipped to manage and administer radioactive drugs for cancer treatment, utilizing cutting-edge imaging systems and radiation protection. All the while, they ensure safety through a team of trained professionals and strict guidelines. Novartis AG, a Swiss pharmaceutical company, in January 2024, unveiled a new automated large-scale facility in Indiana for radioligand therapy (RLT) production. This site, which has been approved by the Food and Drug Administration (FDA) for commercial manufacturing, spans over 70,000 square feet, making it the largest and most advanced Novartis facility devoted to RLT. Designed to allow efficient, time-bound production, it also foresees fully automated production chains to drastically increase supply volumes, addressing the rising demands of patients in the US and Canada.

What Are The Primary Segments Covered In The Global Radioligand Therapy Market Report?

The radioligand therapy market covered in this report is segmented

- 1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
- 2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
- 3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
- 4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
- 5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

- 1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
- 2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
- 3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
- 4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

View the full radioligand therapy market report:

<https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report>

Which Region Is Forecasted To Grow The Fastest In The Radioligand Therapy Industry?

In 2024, the radioligand therapy market was predominantly led by North America. However, the forecast period anticipates Asia-Pacific to be the region with the fastest growth. The report on the global market for radioligand therapy encompasses regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the [Global Radioligand Therapy Market 2025](#), By [The Business Research Company](#)

Property Management Service Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report>

Financial Accounting Advisory Services Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report>

Residential Real Estate Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/residential-real-estate-global-market-report>

[report](#)

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+ +44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/848470605>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.